Recently a new member of the human tumor necrosis factor (TNF) family named as VEGI was reported. However, very little is known about the biological activities displayed by this cytokine. In this report, we show that in myeloid cells VEGI activated the transcription factor kB (NF-kB) as determined by the electrophoretic mobility shift assay, induced degradation of IkBa, and nuclear translocation of p65 subunit of NFkB. VEGI also activated NF-kB-dependent reporter gene expression. In addition, VEGI activated c-Jun Nterminal kinase. When examined for growth modulatory eects, VEGI inhibited the proliferation of breast carcinoma (MCF-7), epithelial (HeLa), and myeloid (U-937 and ML-1a) tumor cells; and activated caspase-3 leading to PARP cleavage. VEGI-induced cytotoxicity was potentiated by inhibitors of protein synthesis. VEGI also induced proliferation of normal human foreskin ®broblast cells. The activity of VEGI could neither be neutralized by antibodies against TNF, nor could it compete with TNF binding, indicating that the activity of VEGI is not due to TNF and it binds to a distinct receptor. These results suggest that VEGI, a new member of the TNF family, has a signaling pathway similar to TNF and is most likely a multifunctional cytokine.
Introduction
The TNF family of cytokines consists of type II transmembrane proteins (except TNFb) and includes TNFa, FasL, CD40L, CD30L, CD27L, 4-1BBL, OX40L (for references see Smith et al., 1994; Aggarwal and Natarajan, 1996) , TRAIL/APO-2L (Wiley et al., 1995; Pitti et al., 1996) , TRANCE (Wong et al., 1997) , TWEAK/DR3L (Chicheportiche et al., 1997; Marsters et al., 1996) , APRIL (Hahne et al., 1998) , LIGHT (Mauri et al., 1998) and THANK (Mukhopadhyay et al., 1999) . These proteins have roles in diverse biological functions such as proliferation, dierentiation, and gene activation (Beutler and van Huel, 1994; Gruss and Dower, 1995; Aggarwal and Natarajan, 1996) . Binding to their cognate receptors initiates several signal transduction pathways that activate NF-kB (Baeuerle and Baltimore, 1996) and of c-jun N-terminal protein kinase, a member of the mitogen-activated protein kinase family (Van Lint et al., 1992; Westwick et al., 1994) . Also activated is a cascade of caspases, ultimately resulting in apoptosis (for references see Darnay and Aggarwal, 1997) . Recently a new member of the TNF family was identi®ed and named as TL1 or VEGI (Tan et al., 1997; Zhai et al., 1999; Yue et al., 1999) . Although its transcript was found in many human tissues, including placenta, lung, kidney, skeletal muscle, pancreas, spleen, prostrate, small intestine and colon, VEGI was expressed most abundantly in endoethelial cells (Tan et al., 1997; Zhai et al., 1999) . It was established that the VEGI gene encodes a type II transmembrane protein with a molecular mass of 13 kD and that it exhibits a 20 ± 30% overall sequence homology to human TNFa, TNFb and the Fas ligand. How VEGI transduces its signal is not yet established. Here we show that VEGI, like TNF, activates NF-kB and c-jun N-terminal kinase, activates caspase-3, and inhibits proliferation of tumor cells while inducing the proliferation of normal human ®broblast cells. Although most of these eects of VEGI are shared with TNF, the protein does not compete for TNF binding sites indicating it has a distinct receptor.
Results and discussion

VEGI binds to receptors distinct from TNF receptors
The identi®cation of VEGI, cloning its cDNA, expression in E. coli, and puri®cation have been described (Tan et al., 1997; Zhai et al., 1999) . Recombinant VEGI corresponding to the putative extracellular domain residues 39 ± 174, was found to be a homogeneous protein of 13 kDa when analysed on SDS ± PAGE (Figure 1a) . Because of its homology to TNF, we examined the binding of VEGI to the TNF receptors using receptor binding assays. While 170 ng/ ml (10 nM) unlabeled TNF blocked the binding of labeled TNF, concentrations of unlabeled VEGI as high as 1950 ng/ml (150 nM) did not compete for binding sites with labeled TNF on U-937 cells ( Figure  1b) . These results suggest that VEGI must interact with cells through a receptor distinct from that of TNF. Alternately, it is also possible that VEGI has very low anity for the TNF receptors.
VEGI activates NF-kB
Activation of NF-kB is one of the events triggered by various members of the TNF family. This activation requires the dissociation of its cytoplasmic heterodimer, composed of the p50 and p65 subunits, from an inhibitory subunit called the IkBa, which is accomplished by the phosphorylation, ubiquitination, and subsequent degradation of IkBa. The p65 subunit of NF-kB moves into the nucleus to bind to speci®c sites on DNA. U-937 cells treated with VEGI for 12 h showed a dose-dependent increase in NF-kB binding to the DNA as shown by electrophoretic mobility shift assay (EMSA) (Figure 2a ): 0.2 mg/ml of VEGI was enough to increase NF-kB binding in these cells, although peak activation was obtained at 1 mg/ml. Study of the kinetics of NF-kB binding showed that 1 mg/ml of VEGI induced a threefold activation of NFkB in 12 h (Figure 2b ) which increased marginally (3.4-fold) at 18 h. Treatment for 24 h, decreased the level of activation to 2.7-fold over basal levels. Higher doses of VEGI (10 mg/ml) activated NF-kB by 2.7-fold within 30 min (data not shown).
To ascertain that the activity observed was due to VEGI and not some contaminant such as endotoxin, we treated VEGI with 1% trypsin or denatured it by exposing it to boiling temperature. Both treatments totally abolished VEGI-induced NF-kB binding in U-937 cells (Figure 2c ), indicating that a protein is responsible for this activity. It is possible that VEGI activates NF-kB through induction of TNF. To explore this possibility, we examined the eect of antibody against TNF on VEGI-induced NF-kB binding. As shown in Figure 2d , anti-TNF antibody blocked TNF-induced NF-kB binding but it did not aect NF-kB binding induced by VEGI. These results indicate that the eects of VEGI are not due to TNF induction.
To determine if NF-kB activated by VEGI consists of p50 and p65 subunits, supershift analysis was performed (Figure 3a) . These results clearly show that VEGI-induced NF-kB band was supershifted by antip50 and anti-p65 antibodies but not by anti-cRel, anticyclin D1 or by the preimmune serum. These results indicate that VEGI-induced NF-kB is composed of p50 and p65 subunits. Like NF-kB activated by other agents, we found that binding of NF-kB induced by VEGI was completely inhibited by the proteaseinhibitor TPCK. We also examined the eect of VEGI on NF-kB-dependent transcription of a reporter gene (Figure 3b ). The result of this experiment indicates that VEGI induces the activation of NF-kBdependent reporter gene in a dose-dependent manner. Under these conditions, heat-denatured VEGI was found to be inactive. Like VEGI, TNF also activated the NF-kB-dependent reporter gene expression in a dose-dependent manner (Figure 3c ). The concentration of TNF required for this eect, however, was much lower than that for VEGI.
U-937 cells treated with VEGI for dierent lengths of time were also examined for degradation of IkBa. Results in Figure 4a show the time course of IkBa degradation in these cells. By 12 h, IkBa is totally degraded and does not reappear even at 24 h, which correlates with the NF-kB activation pro®le. The NFkB-dependent resynthesis of IkBa occurred at 48 h.
When treated with VEGI, no p65 could be detected in the nucleus until 6 h ( Figure 4b) . By 12 h, when activation of NF-kB and degradation of IkB is seen, p65 can be noted in the nucleus. Until 24 h, nuclear p65 can be seen, which explains the almost constant level of NF-kB from 12 ± 24 h. 
VEGI activates c-Jun N-terminal kinase
Activation of c-jun kinase (JNK) is another early event initiated by members of the TNF family and a large number of other stress stimuli. After a 12-h treatment, VEGI induced a dose-dependent activation of c-Jun kinase in U-937 cells without any signi®cant change in the overall amount of JNK protein ( Figure 5a ). By 6 h, a twofold increase in JNK activity could be seen, which further increased to 3.6-fold by 12 h. Further treatment, up to 24 h, did not change the level of activation signi®cantly (Figure 5b ). Unlike TNF, VEGI induced a more persistent activation of c-jun kinase. Though activation of this kinase is generally a transient phenomenon, there have been instances of persistent activation (Chen et al., 1996) . Because of the time required it is, however, possible that VEGI activates JNK through induction of TNF. To explore this possibility, we examined the eect of antibody against TNF on VEGI-induced JNK activation. As shown in Figure 2 (a) Dose response of VEGI-induced NF-kB activation. U-937 cells (2610 6 /ml) were treated with dierent concentrations of VEGI for 12 h at 378C. (b) U-937 cells (2610 6 /ml) were treated with 1 mg/ml of VEGI for dierent lengths of time at 378C. (c) Eect of trypsinization and boiling on the activity of VEGI. VEGI (1 mg/ml) was treated with 1% trypsin for 1 h at room temperature and then checked for its ability to activate NF-kB in U-937 cells (lane 4). Eect of trypsin alone is shown in lane 3. VEGI was also boiled at 1008C for 10 min and then checked for its activity (lane 5). Lanes 1 and 2 show the NF-kB status in untreated and VEGI-treated cells. (d) Eect of anti-TNF antibody on activation of NF-kB induced by TNF and VEGI. TNF (17 ng/ml) and VEGI (1 mg/ml) were treated with anti-TNF antibody for 1 h at room temperature and then exposed to U-937 cells (2610 6 /ml) for either 15 min (TNF) or 12 h (VEGI) at 378C and then assayed for NF-kB activation Figure 5c , anti-TNF antibody blocked TNF-induced JNK activation but had no eect on JNK activation induced by VEGI. These results indicate that the eects of VEGI are not mediated through TNF. This is consistent with a recent report that VEGI can directly activate JNK in endothelial cells (Yue et al., 1999) .
VEGI regulates cell growth
VEGI inhibited the growth of various human tumor cell lines including human histiocytic lymphoma (U-937), human breast carcinoma (MCF-7), human epithelial carcinoma (HeLa) and human myeloid lymphoma ML-1a (Table 1) . When a protein synthesis inhibitor such as cycloheximide was used, cells were further sensitized to the cytotoxic eects of VEGI, reducing the time (24 h vs 96 h) and dose required ( Figure 6a ). The eects of VEGI were more pronounced with U-937 cells than MCF-7 cells. One of the hallmarks of apoptosis is the activation of caspase-3 (also called CPP32/Yama/apopain), which cleaves several cellular proteins including PARP. We found that treatment of cells with VEGI for 2.5 h cleaved PARP in U-937 cells (Figure 6b ). This suggests Figure 3 (a) Supershift analysis of VEGI-activated NF-kB. Nuclear extracts were prepared from VEGI (10 mg/ml)-treated U-937 cells (2610 6 /ml), incubated for 15 min with either the antibodies indicated or with TPCK, and then assayed for the NF-kB activation. (b, c) Eect of VEGI (b) and TNF (c) on the NF-kB-dependent reporter gene (SEAP) expression. U-937 cells were transiently transfected with the SEAP plasmids and then activated with dierent concentrations of either VEGI or TNF for 24 h and assayed for alkaline phosphatase activity as described in Materials and methods. Results are expressed as the fold increase in activity over the untreated control. The results shown are the mean+s.e.m. of triplicate assays. VEGI was heat-denatured by incubation at 1008C for 10 min that VEGI-induced apoptosis, like TNF, is mediated through activation of caspase-3. This is consistent with a recent report that VEGI can directly activate apoptosis in endothelial cells (Yue et al., 1999) .
VEGI was also found to induce proliferation in normal human diploid foreskin ®broblasts, an activity similar to that of TNF (Totpal et al., 1994) . A 72-h treatment of these cells with a range of VEGI concentrations led to proliferation, a ®vefold increase occurring at 10 mg/ml (Figure 6c ).
To further ascertain that the antiproliferative eects of VEGI on dierent cell lines were direct and not mediated through TNF, we examined the eect of antibody against TNF on VEGI-induced eect in dierent cell types. As shown in Figure 7 , anti-TNF antibody abrogated the antiproliferative eects of TNF but it had no eect on growth-suppression induced by VEGI. These results indicate that the eects of VEGI are not due to TNF induction. These results also show that treatment of VEGI with trypsin or heatdenaturation abolishes its antiproliferative activity. These results suggest that the growth-modulatory eects of VEGI are due to a protein.
The relatively low potency of VEGI could be partly due to an unoptimized truncation site or the lack of posttranslational modi®cations such as glycosylation since the protein was expressed in E. coli or due to incorrect folding. Besides, several cytokines which both belong to TNF family and others have been reported to work in comparable concentration ranges as VEGI including TWEAK (stands for a weak homologue of TNF, Chicheportiche et al., 1997; Marsters et al., 1996) , angiostatin (O'Reilly et al., 1994) , endostatin (Good et al., 1990) , CD40 ligand (Mazzei et al., 1995) , IL-18 (Torigoe et al., 1997) , and TRANK (Haridas et al., 1998) . Chicheportiche et al. (1997) have classi®ed various members of the TNF family into three categories, based on their ability to induce apoptosis, as potent inducers (e.g. TNF and Fas), weak inducers (e.g. TWEAK, LT-b, CD30L, and CD-27L) and those which lack the ability to induce cell death (e.g. CD40L, OX-40L, 4-1BBL).
In concert with its sequence homology to TNF, VEGI appears to share several biological activities of TNF. Since it binds to a dierent receptor, however, it remains to be seen if the signaling pathway and the components involved are also the same as TNF. In any case, VEGI appears to be a multipotential cytokine and thus may play a role in in¯ammation, septic shock, fever, viral replication, and growth modulation. /ml) were treated with dierent concentrations of VEGI for 12 h at 378C and assayed for JNK activation as described in the Materials and methods. (b) Kinetics of VEGIinduced activation of JNK in U-937 cells. U-937 cells (3610 6 /ml) were treated with 1 mg/ml of VEGI for dierent lengths of time and assayed for JNK activation. (c) Eect of anti-TNF antibody on activation of JNK induced by TNF and VEGI. TNF (17 ng/ ml) and VEGI (1000 ng/ml) were treated with anti-TNF antibody for 1 h at room temperature and then exposed to U-937 cells (2610 6 /ml) for either 15 min (TNF) or 12 h (VEGI) at 378C and then assayed for JNK activation Because VEGI expression is restricted to endothelial cells, most of these activities may be exhibited locally.
Recently we have found that VEGI is a potent inhibitor of angiogenesis and it inhibits the growth of
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Relative cell viability (%) Figure 6 (a) Eect of VEGI on the relative cell viability of U-937 and MCF-7 cells. Cells (10610 3 /0.1 ml) were treated with dierent concentrations of VEGI in the presence or absence of cycloheximide (CHX) (1 mg/ml) in 96-well plates for 24 h at 378C. Cell viability was measured by the MTT method (for U-937 cells) and crystal violet method (for MCF-7) cells. Results are expressed as per cent viability with CHX alone as 100%. The viability of cells after treatment with CHX (1 mg/ml) for 24 h was 80 ± 83%. (b) VEGI-induced cleavage of PARP in U-937 cells. Cells (2610 6 /ml) were treated with 10 mg/ml of VEGI in the presence of cycloheximide (1 mg/ml) for 2.5 h at 378C. PARP cleavage was assayed as described in the Materials and methods. (c) Eect of VEGI on the proliferation of human diploid foreskin ®broblasts. Fibroblasts (5000/0.1 ml) were cultured with dierent concentrations of VEGI for 72 h at 378C in 96-well plates. During the last 24 h cells were pulse treated with 0.5 mCi/well of tritiated thymidine, and the uptake of thymidine was used as a measure of proliferation Activation of NF-kB, JNK and apoptosis by VEGI V Haridas et al endothelial cells in vitro and suppresses the growth of colon carcinoma in vivo and induces apoptosis in endothelial cells (Yue et al., 1999) .
Materials and methods
Methods
Bacteria-derived human rTNF, puri®ed to homogeneity with a speci®c activity of 5610 7 U/mg, was kindly provided by Genentech (South Francisco, CA, USA). Penicillin, streptomycin, RPMI 1640 medium, and FBS were obtained from Life Technologies (Grand Island, NY, USA). Tris, glycine, NaCl, SDS, PMA, TPCK, and BSA were obtained from Sigma Chemical Co. (St Louis, MO, USA). The polyclonal antibodies against IkBa, p65, p50, anti-cRel, anti-cyclin D1 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Receptor-binding assays
Receptor-binding assays were performed as described previously (Higuchi and Aggarwal, 1992) . TNF was labeled with Na 125 I (Amersham Life Sciences, Arlington Heights, IL, USA) using the iodogen method to an approximate speci®c activity of 40 mCi/mg. Binding assays were performed in exible 96-well plates. U-937 cells (0.5610 6 /0.1 ml) were incubated in a binding medium (RPMI-1640 containing 10% FBS) with 125 I-labeled TNF in the absence (total binding) or presence of 170 ng/ml (10 nM) unlabeled TNF (nonspeci®c binding) or VEGI (1950 ng/ml or 150 nM) for 1 h at 48C. Thereafter, cells were washed three times with ice-cold medium (PBS containing 0.1% BSA) at 48C, and the cellbound radioactivity was determined in a gamma counter (Cobra-AutoGamma, Packard Instrument Co., Downers Grove, IL, USA). All determinations were performed in triplicate.
Cytotoxicity and proliferation assays
The sensitivity of nonadherent cells (U-937 and ML-1a) to VEGI was determined by the modi®ed tetrazolium salt (MTT) assay, while that of the adherent cells (MCF-7 and HeLa) was studied by the crystal violet method, both of which have been described earlier (Hansen et al., 1989; Aggarwal, 1985) .
The cell growth-stimulatory eect of VEGI was studied in normal human diploid foreskin ®broblasts by the method described (Totpal et al., 1994) .
Immunoblot analysis of PARP degradation
VEGI-induced apoptosis was also examined by proteolytic cleavage of poly (ADP-ribose) polymerase (PARP) (Tewari et al., 1995) . Brie¯y, U-937 cells (2610 6 /ml) were treated with VEGI (10 mg) for 2.5 h in the presence of 1 mg/ml cycloheximide. After treatment, cell extracts were prepared as described earlier. Cell extract protein (50 mg) was resolved on a 7.5% SDS polyacrylamide gel, electrotransferred onto a nitrocellulose membrane, blotted ®rst with mouse anti-PARP antibody and then with anti-mouse HRPO conjugated IgG as the secondary antibody, and then detected by chemiluminescence (ECL; Amersham). Apoptosis was measured by the Figure 7 Eect of anti-TNF antibodies, trypsin-treatment and heat-denaturation on the cytotoxic eects of VEGI against U-937, ML-1a, Hela and MCF-7 cells. VEGI (1 mg/ml) was treated with anti-TNF antiserum at room temperature for 1 h or treated with 1% trypsin for 1 h at room temperature or boiled at 1008C for 10 min and then checked. Cells were plated in 96-well plates at 5610 4 /0.1 ml, treated with 10 mg/ml of VEGI for 72 h and then examined for cell viability by MTT method extent of cleavage of 116-kDa PARP into 85-kDa and 41-kDa peptide products (Tewari et al., 1995) .
Electrophoretic mobility shift assays
An electrophoretic mobility shift assay (EMSA) to examine NF-kB activation was conducted as described earlier (Singh and Aggarwal, 1995a; Schreiber et al., 1989) . Brie¯y, cells (
/ml) were treated with dierent concentrations of VEGI at 378C for 12 h. Nuclear extracts were then prepared, and EMSA was performed as described (Schreiber et al., 1989) . EMSA was performed by incubating 4 mg of NE with 16 fmol of 32 P-end-labeled 45-mer double-stranded NF-kB oligonucleotide from the HIV-1 long terminal repeat, 5'-TT-GTTACAAGGGACTTTCCGCTG GGGACTTTCCAGGG AGGCGTGG-3', in the presence of 2 ± 5 mg of poly (dI : dC) in a binding buer (25 mM HEPES, pH 7.9, 0.5 mM EDTA, 0.5 mM DTT, 1% Nonidet P-40, 5% glycerol, and 50 mM NaCl) for 15 min at 378C. The DNA protein complex formed was separated from free oligonucleotide on a 7.5% native polyacrylamide gel. The speci®city of binding was also checked by using a labeled mutant oligonucleotide, by competition with the unlabeled oligonucleotide and by supershift with NF-kB-speci®c antibodies as described (Schreiber et al., 1989) . The radioactive bands from dried gels were visualized on a Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA) and quantitated using Image-quant software.
NF-kB SEAP reporter assay
To construct a synthetic NF-kB-containing promoter element, a PCR-based strategy was used. The upstream primer (5'-GCGGCCTCGAGGGGACTTTCCCGGGGAC-TTTCCGGGGACTTTCCGGGACTTTCCATCCTGCCAT-CTCAATTAG-3') contained four tandem copies of the NFkB binding site (GGGGACTTTCCC) and 18 bp of a sequence complementary to the 5' end of the SV40 early promoter sequence, and was¯anked with an XhoI site. The downstream primer (5'-GCGGCAAGCTTTTTGCAA-AGCCTAGGC-3') was complementary to the 3' end of the SV40 promoter and was¯anked with a HindIII site. PCR was performed using the SV40 promoter template. The resulting PCR fragment was digested with XhoI/HindIII and subcloned into a likewise digested SEAP2-promoter plasmid to replace the SV40 minimal promoter element.
Human U-937 cells were transiently transfected with pNFkB-SEAP2 (0.5 mg), and then treated with VEGI or TNF. After 24 h at 378C, the conditioned medium was removed and assayed for SEAP activity essentially as described by the manufacturer (Clontech, Palo Alto, CA, USA). In brief, medium (25 ml) was mixed with 30 ml of 56buer (500 mM TRIS, pH 9, and 0.5% bovine serum albumin) in a total volume of 100 ml in a 96-well plate and incubated at 658C for 30 min. The plate was chilled on ice for 2 min. Then 50 ml of 1 mM 4-methylumbelliferyl phosphate was added to each well and incubated at 378C for 2 h. The activity of SEAP was assayed on a 96-well¯uorescent plate reader (Fluoroscan II, Lab Systems, Needham, Heights, MA, USA) with excitation set at 360 nm and emission at 460 nm. The average (means+s.d.) number of relative¯uorescent light units for each transfection was then determined and reported as fold activation with respect to untreated cells.
Western blotting for IkB and p65
Cytoplasmic and nuclear extracts of U-937 cells treated with VEGI for dierent times were used to examine levels of IkB and the p65 subunit of NF-kB, respectively, by the procedure described earlier (Singh and Aggarwal, 1995b) . Brie¯y, the cytoplasmic extracts (CE) from treated cells were resolved on 10% SDS-polyacrylamide gels for IkBa. To determine p65 levels, nuclear extracts were resolved on 9% SDS-polyacrylamide gels, electrotransferred to Immobilon P membranes, probed with a rabbit polyclonal antibody against p65, and detected by chemiluminescence (ECL-Amersham).
c-Jun kinase assay
The c-jun kinase assay was performed as described by Derijard et al. (1994) with some modi®cations detailed in Kumar et al. (1998) . Brie¯y, after treatment of cells (3610 6 / ml) with VEGI, cell extracts were prepared by lysing cells in buer containing 20 mM HEPES pH 7.4, 2 mM EDTA, 250 mM NaCl, 0.1% NP-40, 2 mg/ml leupeptin, 2 mg/ml aprotinin, 1 mM PMSF, 0.5 mg/ml benzamidine, and 1 mM DTT. Cell extracts (150 ± 250 mg) were subjected to immunoprecipitation with 0.03 mg anti-JNK antibody for 30 min at 48C. Immune complexes were collected by incubation with protein A/G-sepharose beads for 30 min at 48C. The beads were collected by centrifugation and washed extensively with lysis buer (46400 ml) and kinase buer (26400 ml; 20 mM HEPES, pH 7.4, 1 mM DTT, 25 mM NaCl). Kinase assays were performed for 15 min at 308C with 2 mg GST-Jun(1 ± 79) in 20 ml containing 20 mM HEPES, pH 7.4, 10 mM MgCl 2 , 1 mM DTT, and 10 mCi [g-32 P]ATP. Reactions were stopped with 15 ml SDS-sample buer, boiled for 5 min, and subjected to SDS ± PAGE. GSTJun(1 ± 79) was visualized by staining with Coomassie Blue, and the dried gel was analysed by a Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA) and quantitated by ImageQuant Software (Molecular Dynamics, Sunnyvale, CA, USA). Abbreviations TNF, tumor necrosis factor; TWEAK, a weak homologue of TNF; TNANK, TNF homologue that activates NF-kB, JNK and apoptosis; NF-kB, nuclear transcription factorkB; IkB, inhibitory subunit of NF-kB; IL, interleukin; EMSA, electrophoretic mobility shift assay; MAPK, mitogen-activated protein kinase; VEGI, vascular endothelial cell-derived growth inhibitor; PARP, poly(A) + (ADPribose) polymerase; DR3L, death receptor-3 ligand.
